Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Practice for preterm patent ductus arteriosus; focusing on the hemodynamic significance and the impact on the neonatal outcomes

  • Lee, Jin A (Division of Neonatology, Department of Pediatrics, Seoul National University College of Medicine)
  • Received : 2018.10.28
  • Accepted : 2019.04.06
  • Published : 2019.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Hemodynamically significant preterm patent ductus arteriosus (PDA) affects mortality; comorbidities such as necrotizing enterocolitis, intraventricular hemorrhage, and bronchopulmonary dysplasia; and adverse long-term neurodevelopmental outcomes in preterm infants, particularly in very low birth weight infants. However, recent studies have indicated that there is no consensus on the causal relationship between PDA and neonatal outcomes, the benefit of PDA treatment, the factors guiding the need for treatment, and optimal treatment strategies. Such uncertainty has resulted in wide variations in practice for treating preterm PDA between units, regions, and nations. Nowadays, there has been a paradigm shift to more conservative treatment for preterm PDA, and suggestions regarding selective management of preterm PDA considering risk factors and hemodynamic significance are increasing. Neonatologist-performed echocardiography and advances in modalities to assess hemodynamic significance such as biologic markers and near-infrared spectroscopy also help improve the efficacy of selective treatment of preterm PDA.

Keywords

References

  1. Clyman RI. The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia. Semin Perinatol 2013;37:102-7. https://doi.org/10.1053/j.semperi.2013.01.006
  2. Noori S, McCoy M, Friedlich P, Bright B, Gottipati V, Seri I, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 2009;123:e138-44. https://doi.org/10.1542/peds.2008-2418
  3. Schena F, Francescato G, Cappelleri A, Picciolli I, Mayer A, Mosca F, et al. Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia. J Pediatr 2015;166:1488-92. https://doi.org/10.1016/j.jpeds.2015.03.012
  4. Evans NJ, Archer LN. Postnatal circulatory adaptation in healthy term and preterm neonates. Arch Dis Child 1990;65(1 Spec No):24-6. https://doi.org/10.1136/adc.65.1_Spec_No.24
  5. Rolland A, Shankar-Aguilera S, Diomande D, Zupan-Simunek V, Boileau P. Natural evolution of patent ductus arteriosus in the extremely preterm infant. Arch Dis Child Fetal Neonatal Ed 2015;100:F55-8. https://doi.org/10.1136/archdischild-2014-306339
  6. Heuchan AM, Clyman RI. Managing the patent ductus arteriosus: current treatment options. Arch Dis Child Fetal Neonatal Ed 2014;99:F431-6. https://doi.org/10.1136/archdischild-2014-306176
  7. Herrman K, Bose C, Lewis K, Laughon M. Spontaneous closure of the patent ductus arteriosus in very low birth weight infants following discharge from the neonatal unit. Arch Dis Child Fetal Neonatal Ed 2009;94:F48-50. https://doi.org/10.1136/adc.2007.129270
  8. Korea Centers for Disease Control and Prevention. Korean Neonatal Network Annual Report 2017. Cheongju (Korea): Korea Centers for Disease Control and Prevention, 2018.
  9. Lee JA, Kim MJ, Oh S, Choi BM. Current status of therapeutic strategies for patent ductus arteriosus in very-low-birth-weight infants in Korea. J Korean Med Sci 2015;30 Suppl 1:S59-66. https://doi.org/10.3346/jkms.2015.30.S1.S59
  10. Zonnenberg I, de Waal K. The definition of a haemodynamic significant duct in randomized controlled trials: a systematic literature review. Acta Paediatr 2012;101:247-51. https://doi.org/10.1111/j.1651-2227.2011.02468.x
  11. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007;92:F424-7. https://doi.org/10.1136/adc.2007.118117
  12. Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005;115:e255-61. https://doi.org/10.1542/peds.2004-1837
  13. Shin J, Lee EH, Lee JH, Choi BM, Hong YS. Individualized ibuprofen treatment using serial B-type natriuretic peptide measurement for symptomatic patent ductus arteriosus in very preterm infants. Korean J Pediatr 2017;60:175-80. https://doi.org/10.3345/kjp.2017.60.6.175
  14. Hu Y, Jin H, Jiang Y, Du J. Prediction of therapeutic response to cyclooxygenase inhibitors in preterm infants with patent ductus arteriosus. Pediatr Cardiol 2018;39:647-52. https://doi.org/10.1007/s00246-018-1831-x
  15. Weisz DE, McNamara PJ, El-Khuffash A. Cardiac biomarkers and haemodynamically significant patent ductus arteriosus in preterm infants. Early Hum Dev 2017;105:41-7. https://doi.org/10.1016/j.earlhumdev.2016.12.007
  16. Kulkarni M, Gokulakrishnan G, Price J, Fernandes CJ, Leeflang M, Pammi M. Diagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review. Pediatrics 2015;135:e510-25. https://doi.org/10.1542/peds.2014-1995
  17. Jeong HA, Shin J, Kim E, Lee EH, Choi BM, Son CS, et al. Correlation of B-type natriuretic peptide levels and echocardiographic parameters in preterm infants with patent ductus arteriosus. Korean J Pediatr 2016;59:183-9. https://doi.org/10.3345/kjp.2016.59.4.183
  18. Ledo A, Aguar M, Nunez-Ramiro A, Saenz P, Vento M. Abdominal near-infrared spectroscopy detects low mesenteric perfusion early in preterm infants with hemodynamic significant ductus arteriosus. Neonatology 2017;112:238-45. https://doi.org/10.1159/000475933
  19. Yum SK, Moon CJ, Youn YA, Lee JY, Sung IK. Echocardiographic assessment of patent ductus arteriosus in very low birthweight infants over time: prospective observational study. J Matern Fetal Neonatal Med 2018;31:164-72. https://doi.org/10.1080/14767058.2016.1278207
  20. Kluckow M, Evans N. Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation. J Pediatr 1995;127:774-9. https://doi.org/10.1016/S0022-3476(95)70172-9
  21. Sehgal A, McNamara PJ. Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus? Eur J Pediatr 2009;168:907-14. https://doi.org/10.1007/s00431-009-0983-3
  22. van Laere D, van Overmeire B, Gupta S, El Khuffash A, Savoia M, McNamara PJ, et al. Application of NPE in the assessment of a patent ductus arteriosus. Pediatr Res 2018 ;84(Suppl 1):46-56. https://doi.org/10.1038/s41390-018-0077-x
  23. de Boode WP, Kluckow M, McNamara PJ, Gupta S. Role of neonatologist-performed echocardiography in the assessment and management of patent ductus arteriosus physiology in the newborn. Semin Fetal Neonatal Med 2018;23:292-7. https://doi.org/10.1016/j.siny.2018.03.007
  24. Sehgal A, Paul E, Menahem S. Functional echocardiography in staging for ductal disease severity : role in predicting outcomes. Eur J Pediatr 2013;172:179-84. https://doi.org/10.1007/s00431-012-1851-0
  25. El-Khuffash A, James AT, Corcoran JD, Dicker P, Franklin O, Elsayed YN, et al. A patent ductus arteriosus severity score predicts chronic lung disease or death before discharge. J Pediatr 2015;167:1354-61.e2. https://doi.org/10.1016/j.jpeds.2015.09.028
  26. Sehgal A, McNamara PJ. International perspective on management of a patent ductus arteriosus: Lessons learned. Semin Fetal Neonatal Med 2018;23:278-84. https://doi.org/10.1016/j.siny.2018.03.002
  27. Wyllie JP, Gupta S. Prophylactic and early targeted treatment of patent ductus arteriosus. Semin Fetal Neonatal Med 2018;23:250-4. https://doi.org/10.1016/j.siny.2018.03.005
  28. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev 2018;9:CD003481.
  29. Mitra S, Florez ID, Tamayo ME, Mbuagbaw L, Vanniyasingam T, Veroniki AA, et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA 2018;319:1221-38. https://doi.org/10.1001/jama.2018.1896
  30. Amendolia B, Lynn M, Bhat V, Ritz SB, Aghai ZH. Severe pulmonary hypertension with therapeutic L-lysine ibuprofen in 2 preterm neonates. Pediatrics 2012;129:e1360-3. https://doi.org/10.1542/peds.2011-0117
  31. Cuzzolin L, Bardanzellu F, Fanos V. The dark side of ibuprofen in the treatment of patent ductus arteriosus: could paracetamol be the solution? Expert Opin Drug Metab Toxicol 2018;14:855-68. https://doi.org/10.1080/17425255.2018.1492550
  32. Zecca E, Romagnoli C, De Carolis MP, Costa S, Marra R, De Luca D. et al. Does Ibuprofen increase neonatal hyperbilirubinemia? Pediatrics 2009;124:480-4. https://doi.org/10.1542/peds.2008-2433
  33. Rheinlaender C, Helfenstein D, Walch E, Berns M, Obladen M, Koehne P. Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants. Acta Paediatr 2009;98:36-42. https://doi.org/10.1111/j.1651-2227.2008.01007.x
  34. El-Farrash RA, El Shimy MS, El-Sakka AS, Ahmed MG, Abdel-Moez DG. Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Matern Fetal Neonatal Med 2018 May 9:1-8. https://doi.org/10.1080/14767058.2018.1470235. [Epub]
  35. Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H. Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One 2013;8:e77888. https://doi.org/10.1371/journal.pone.0077888
  36. Oncel MY, Yurttutan S, Erdeve O, Uras N, Altug N, Oguz SS, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Pediatr 2014;164:510-4.e1. https://doi.org/10.1016/j.jpeds.2013.11.008
  37. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev 2018;4:CD010061.
  38. Mirea L, Sankaran K, Seshia M, Ohlsson A, Allen AC, Aziz K, et al. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. J Pediatr 2012;161:689-94.e1. https://doi.org/10.1016/j.jpeds.2012.05.007
  39. Bourgoin L, Cipierre C, Hauet Q, Basset H, Gournay V, Roze JC, et al. Neurodevelopmental outcome at 2 years of age according to patent ductus arteriosus management in very preterm infants. Neonatology 2016;109:139-46. https://doi.org/10.1159/000442278
  40. Weisz DE, Mirea L, Resende MHF, Ly L, Church PT, Kelly E, et al. Outcomes of surgical ligation after unsuccessful pharmacotherapy for patent ductus arteriosus in neonates born extremely preterm. J Pediatr 2018;195:292-6.e3. https://doi.org/10.1016/j.jpeds.2017.11.029
  41. Pamukcu O, Tuncay A, Narin N, Baykan A, Korkmaz L, Argun M, et al. Patent ductus arteriosus closure in preterms less than 2 kg: surgery versus transcatheter. Int J Cardiol 2018;250:110-5. https://doi.org/10.1016/j.ijcard.2017.10.020
  42. Morville P, Akhavi A. Transcatheter closure of hemodynamic significant patent ductus arteriosus in 32 premature infants by amplatzer ductal occluder additional size-ADOIIAS. Catheter Cardiovasc Interv 2017;90:612-7. https://doi.org/10.1002/ccd.27091
  43. Morville P, Douchin S, Bouvaist H, Dauphin C. Transcatheter occlusion of the patent ductus arteriosus in premature infants weighing less than 1200 g. Arch Dis Child Fetal Neonatal Ed 2018;103:F198-201. https://doi.org/10.1136/archdischild-2016-312582
  44. Garg G, Garg V, Prakash A. Percutaneous closure of a large patent ductus arteriosus in a preterm newborn weighing 1400 g without using arterial sheath: an innovative technique. Cardiol Young 2018;28:494-7. https://doi.org/10.1017/S1047951117002475
  45. Pavlek LR, Slaughter JL, Berman DP, Backes CH. Catheter-based closure of the patent ductus arteriosus in lower weight infants. Semin Perinatol 2018;42:262-8. https://doi.org/10.1053/j.semperi.2018.05.009
  46. Backes CH, Cheatham SL, Deyo GM, Leopold S, Ball MK, Smith CV, et al. Percutaneous patent ductus arteriosus (PDA) closure in very preterm infants: feasibility and complications. J Am Heart Assoc 2016 Feb 12;5(2). pii: e002923. https://doi.org/10.1161/JAHA.115.002923.
  47. Abu Hazeem AA, Gillespie MJ, Thun H, Munson D, Schwartz MC, Dori Y, et al. Percutaneous closure of patent ductus arteriosus in small infants with significant lung disease may offer faster recovery of respiratory function when compared to surgical ligation. Catheter Cardiovasc Interv 2013;82:526-33. https://doi.org/10.1002/ccd.25032
  48. Semberova J, Sirc J, Miletin J, Kucera J, Berka I, Sebkova S, et al. Spontaneous closure of patent ductus arteriosus in infants $\leq$1500 g. Pediatrics 2017 Aug;140(2). pii: e20164258. https://doi.org/10.1542/peds.2016-4258. Epub 2017 Jul 12.
  49. Letshwiti JB, Semberova J, Pichova K, Dempsey EM, Franklin OM, Miletin J. A conservative treatment of patent ductus arteriosus in very low birth weight infants. Early Hum Dev 2017;104:45-9. https://doi.org/10.1016/j.earlhumdev.2016.12.008
  50. Sung SI, Chang YS, Chun JY, Yoon SA, Yoo HS, Ahn SY, et al. Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. J Pediatr 2016;177:66-71.e1. https://doi.org/10.1016/j.jpeds.2016.06.046
  51. Liebowitz M, Koo J, Wickremasinghe A, Allen IE, Clyman RI. Effects of prophylactic indomethacin on vasopressor-dependent hypotension in extremely preterm infants. J Pediatr 2017;182:21-7.e2. https://doi.org/10.1016/j.jpeds.2016.11.008
  52. Liebowitz M, Clyman RI. Prophylactic indomethacin compared with delayed conservative management of the patent ductus arteriosus in extremely preterm infants: effects on neonatal outcomes. J Pediatr 2017;187:119-26.e1. https://doi.org/10.1016/j.jpeds.2017.03.021
  53. Jensen EA, Dysart KC, Gantz MG, Carper B, Higgins RD, Keszler M, et al. Association between use of prophylactic indomethacin and the risk for bronchopulmonary dysplasia in extremely preterm infants. J Pediatr 2017;186:34-40.e2. https://doi.org/10.1016/j.jpeds.2017.02.003
  54. Jensen EA, Foglia EE, Schmidt B. Association between prophylactic indomethacin and death or bronchopulmonary dysplasia: a systematic review and meta-analysis of observational studies. Semin Perinatol 2018;42:228-34. https://doi.org/10.1053/j.semperi.2018.05.005
  55. Ding Y, Wang X, Wu Y, Li H, Xu J, Wang X. Effects of prophylactic oral ibuprofen on the closure rate of patent ductus arteriosus in premature infants. Medicine (Baltimore) 2018;97:e12206. https://doi.org/10.1097/MD.0000000000012206
  56. Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2011;(7):CD004213.
  57. Lokku A, Mirea L, Lee SK, Shah PS; Canadian Neonatal Network. Trends and outcomes of patent ductus arteriosus treatment in very preterm infants in Canada. Am J Perinatol 2017;34:441-50. https://doi.org/10.1055/s-0036-1593351
  58. Hagadorn JI, Brownell EA, Trzaski JM, Johnson KR, Lainwala S, Campbell BT, et al. Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus. Pediatr Res 2016;80:785-92. https://doi.org/10.1038/pr.2016.166
  59. Ngo S, Profit J, Gould JB, Lee HC. Trends in patent ductus arteriosus diagnosis and management for very low birth weight infants. Pediatrics 2017 Apr;139(4). pii: e20162390. https://doi.org/10.1542/peds.2016-2390.
  60. Bixler GM, Powers GC, Clark RH, Walker MW, Tolia VN. Changes in the diagnosis and management of patent ductus arteriosus from 2006 to 2015 in United States neonatal intensive care units. J Pediatr 2017;189:105-12. https://doi.org/10.1016/j.jpeds.2017.05.024
  61. Chock VY, Goel VV, Palma JP, Luh TM, Wang NA, Gaskari S, et al. Changing management of the patent ductus arteriosus: effect on neonatal outcomes and resource utilization. Am J Perinatol 2017;34:990-5. https://doi.org/10.1055/s-0037-1601442
  62. Benitz WE, Bhombal S. The use of non-steroidal anti-inflammatory drugs for patent ductus arteriosus closure in preterm infants. Semin Fetal Neonatal Med 2017;22:302-7. https://doi.org/10.1016/j.siny.2017.07.004
  63. Ezenwa B, Pena E, Schlegel A, Bapat R, Shepherd EG, Nelin LD. Effects of practice change on outcomes of extremely preterm infants with patent ductus arteriosus. Acta Paediatr 2019;108:88-93. https://doi.org/10.1111/apa.14423
  64. Collins RT 2nd, Lyle RE, Rettiganti M, Gossett JM, Robbins JM, Casey PH. Long-term neurodevelopment of low-birthweight, preterm infants with patent ductus arteriosus. J Pediatr 2018;203:170-6.e1. https://doi.org/10.1016/j.jpeds.2018.08.004
  65. Clyman RI. Patent ductus arteriosus, its treatments, and the risks of pulmonary morbidity. Semin Perinatol 2018;42:235-42. https://doi.org/10.1053/j.semperi.2018.05.006
  66. Hagadorn JI, Bennett MV, Brownell EA, Payton KSE, Benitz WE, Lee HC. Covariation of neonatal intensive care unit-level patent ductus arteriosus management and in-neonatal intensive care unit outcomes following preterm birth. J Pediatr 2018;203:225-33.e1. https://doi.org/10.1016/j.jpeds.2018.07.025
  67. Jhaveri N, Moon-Grady A, Clyman RI. Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment. J Pediatr 2010;157:381-7, 387.e1. https://doi.org/10.1016/j.jpeds.2010.02.062
  68. Weisz DE, Mirea L, Rosenberg E, Jang M, Ly L, Church PT, et al. Association of patent ductus arteriosus ligation with death or neurodevelopmental impairment among extremely preterm infants. JAMA Pediatr 2017;171:443-9. https://doi.org/10.1001/jamapediatrics.2016.5143
  69. Mashally S, Nield LE, McNamara PJ, Martins FF, El-Khuffash A, Jain A, et al. Late oral acetaminophen versus immediate surgical ligation in preterm infants with persistent large patent ductus arteriosus. J Thorac Cardiovasc Surg 2018;156:1937-44. https://doi.org/10.1016/j.jtcvs.2018.05.098
  70. de Boode WP, Singh Y, Gupta S, Austin T, Bohlin K, Dempsey E, et al. Recommendations for neonatologist performed echocardiography in Europe: Consensus Statement endorsed by European Society for Paediatric Research (ESPR) and European Society for Neonatology (ESN). Pediatr Res 2016;80:465-71. https://doi.org/10.1038/pr.2016.126
  71. O'Rourke DJ, El-Khuffash A, Moody C, Walsh K, Molloy EJ. Patent ductus arteriosus evaluation by serial echocardiography in preterm infants. Acta Paediatr 2008;97:574-8. https://doi.org/10.1111/j.1651-2227.2008.00745.x
  72. Roze JC, Cambonie G, Marchand-Martin L, Gournay V, Durrmeyer X, Durox M, et al. Association between early screening for patent ductus arteriosus and in-hospital mortality among extremely preterm infants. JAMA 2015;313:2441-8. https://doi.org/10.1001/jama.2015.6734

Cited by

  1. Controversy in the diagnosis and treatment of hemodynamically significant patent ductus arteriosus in preterm infants vol.62, pp.11, 2019, https://doi.org/10.3345/kjp.2019.00570
  2. Discriminant Analysis of Main Prognostic Factors Associated with Hemodynamically Significant PDA: Apgar Score, Silverman-Anderson Score, and NT-Pro-BNP Level vol.10, pp.16, 2019, https://doi.org/10.3390/jcm10163729